Bumpus F M, Khosla M C
Mayo Clin Proc. 1977 Jul;52(7):417-23.
The complex hormonal action of angiotensin II in the long-term control of blood pressure or sodium metabolism, or in renal hypertension, is not completely understood. Structure-activity relations with analogues of angiotensin II gave information about the functions responsible for pressor and myotropic response in the molecule that led to the synthesis of competitive antagonists of this hormone. These antagonists, however, show variable agonist/antagonist ratios in different species or different tissues of the same species. This fact necessitates further work to induce tissue specificity. Although des-Asp1-angiotensin II ("angiotensin III") has been recognized as a hormone, its exact role in the biosynthesis of aldosterone is yet to be discovered. The antagonists such as des-Asp1-[Ile8]-angiotensin II or des-Asp1-[Thr8]-angiotensin II have provided important leads in this direction. Many of the biologic effects of angiotensin I have been attributed to its conversion to angiotensin II by the converting enzyme. Recent investigations indicate that angiotensin I itself may play a direct role; however, most of these studies were carried out by inhibiting the converting enzyme activity with peptides obtained from the venom of Bothrops jararaca. Since these peptides also potentiate bradykinin action, the observed biologic activities could be caused by either angiotensin I or bradykinin. Bsides, converting enzyme is no longer thought to be a single enzyme and its nature varies from species to species and from tissue to tissue in the same species. Renin inhibitors related to renin substrate or pepstatin are not freely soluble in plasma and are not effective under physiologic conditions. This points to the importance of renin inhibitors isolated from kidney or other natural sources. Thus, although the renin-angiotensin system appears to be an integral part of the problem of hypertension, characterization of various converting enzymes, roles of extrarenal renin, isorenin, tonin, and brain-renin, and the involvement of other humoral, neurogenic, and immunogenic factors should be pieced together to get a clear picture of the hypertension problem.
血管紧张素II在血压长期调控、钠代谢或肾性高血压方面的复杂激素作用尚未完全明确。与血管紧张素II类似物的构效关系为了解该分子中引起升压和肌性反应的功能提供了信息,进而促成了这种激素竞争性拮抗剂的合成。然而,这些拮抗剂在不同物种或同一物种的不同组织中表现出不同的激动剂/拮抗剂比例。这一事实使得有必要开展进一步工作以诱导组织特异性。尽管去天门冬氨酸1 -血管紧张素II(“血管紧张素III”)已被确认为一种激素,但其在醛固酮生物合成中的确切作用仍有待发现。诸如去天门冬氨酸1 - [异亮氨酸8] -血管紧张素II或去天门冬氨酸1 - [苏氨酸8] -血管紧张素II等拮抗剂已在此方向上提供了重要线索。血管紧张素I的许多生物学效应归因于其被转换酶转化为血管紧张素II。近期研究表明血管紧张素I本身可能起直接作用;然而,这些研究大多是通过用从矛头蝮蛇毒液中获得的肽抑制转换酶活性来进行的。由于这些肽也增强缓激肽的作用,所观察到的生物学活性可能由血管紧张素I或缓激肽引起。此外,现在认为转换酶不再是单一的酶,其性质因物种不同以及同一物种的不同组织而异。与肾素底物或胃蛋白酶抑制剂相关的肾素抑制剂在血浆中溶解度不佳,在生理条件下无效。这表明从肾脏或其他天然来源分离的肾素抑制剂的重要性。因此,尽管肾素 - 血管紧张素系统似乎是高血压问题的一个组成部分,但需要综合各种转换酶的特性、肾外肾素、同种肾素、高血压素和脑肾素的作用,以及其他体液、神经源性和免疫源性因素的参与情况,才能全面了解高血压问题。